Neuroscience research has been revolutionized by the use of recombinant viral vector technology from the basic, preclinical and clinical levels. Currently, multiple recombinant viral vector types are employed with each having its strengths and weaknesses depending on the proposed application. Helper-dependent adenoviral vectors (HdAd) are emerging as ideal viral vectors that solve a major need in the neuroscience field: (1) expression of transgenes that are too large to be packaged by other viral vectors and (2) rapid onset of transgene expression in the absence of cytotoxicity. Here, we describe the methods for large-scale production of HdAd viral vectors for in vivo use with neurospecific transgene expression.
You may also like
Amygdala Intercalated Cells: Gatekeepers and Conveyors...
January 19, 2023Max Planck Florida Institute for Neuroscience
In the zone for memories
January 10, 2023Max Planck Institute for Brain Research
How visual information travels from the retina to the...
October 6, 2022Max Planck Institute for Biological Intelligence
Different flavors of inhibition save the day
August 23, 2022Max Planck Institute for Brain Research
Gamma rhythms – a phenomenon simpler than...
August 1, 2022Ernst Strüngmann Institute for Neuroscience
Silence for thought: special interneuron networks in...
June 27, 2022Max Planck Institute for Brain Research